

GNVPN.019B1USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1632
)
James M. Wilson et al) Examiner: J. Martin
)
Appln. No.:)
)
Filed: Herewith)
)
For: METHOD FOR RECOMBINANT) January 10, 2001
ADENO-ASSOCIATED VIRUS-)
DIRECTED GENE THERAPY)

Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified patent application as follows.

In the Claims

Cancel claims 1-6 without prejudice.

REMARKS

After entry of this preliminary amendment, the pending claims are claims 7-10. Claims 1-6 are canceled. No new matter is introduced by this preliminary amendment.

Applicants respectfully request that this preliminary amendment be entered prior to calculating the filing fees.


Express Mail No. EK99270341345

The Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for the Applicants

By


Cathy A. Kodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9210
Telefacsimile: (215) 540-5818

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of) Group Art Unit: 1632
)
James M. Wilson et al) Examiner: J. Martin
)
Appln. No.:)
)
Filed: Herewith)
)
For: METHOD FOR RECOMBINANT) January 10, 2001
ADENO-ASSOCIATED VIRUS-)
DIRECTED GENE THERAPY)

Assistant Commissioner for Patents
Washington, DC 20231

SECOND PRELIMINARY AMENDMENT

Sir:

Please amend the above-identified patent application as follows.

In the Specification

Page 1, line 6, before "Background of the Invention", insert

-- **Cross-Reference to Related Application**

This is a continuation of U. S. Patent Application No. 09/242,977, filed February 26, 1999, which is a §371 of PCT/US97/15692, filed September 4, 1997, which is a continuation-in-part of U. S. Patent Application No. 08/708,188, filed September 6, 1996 and now U. S. Patent No. 5,866,552 and a continuation-in-part of U. S. Patent Application No. 08/729,061, filed October 10, 1996, now abandoned. --

Please enter the attached Abstract of the Disclosure on the attached page.

Express Mail No. EK99270341345

In the Claims

Add new claim 11 as follows.

11. A method of delivering a selected transgene to an animal comprising the steps of providing a recombinant adeno-associated virus comprising a selected transgene (rAAV) operably linked to sequences which control expression thereof and administering the rAAV to the animal intramuscularly.

REMARKS

Upon entry of this second preliminary amendment, the claims pending are Claims 7-11. Support for new claim 11 may be found throughout the specification. No new matter is added by this preliminary amendment.

The attached Abstract of the Disclosure is supported throughout the specification.

Applicants respectfully request consideration of the pending claims.

The Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for the Applicants

By



Cathy A. Rodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9210
Telefacsimile: (215) 540-5818

ABSTRACT OF THE DISCLOSURE

A method of prolonging gene expression by reducing immune response to a recombinant adeno-associated virus (AAV) bearing a desired gene administered into the muscle of a mammal is described.

1. A method of prolonging gene expression by reducing immune response to a recombinant adeno-associated virus (AAV) bearing a desired gene administered into the muscle of a mammal is described.